Spore.Bio, a deeptech startup specializing in AI-assisted microbiological control, has secured a $23 million Series A funding round, just a year after raising $8.3 million in seed funding. The round was led by European venture capital firm Singular, with participation from Point 72 Ventures, LocalGlobe, 1st Kind Ventures (Peugeot family office), Station F, and Lord David Prior, former chairman of the UK’s National Health Service (NHS).
Founded in 2023 by Amine Raji (CEO), Maxime Mistretta (CTO), and Mohamed Tazi (COO), Spore.Bio is revolutionizing microbiological quality control with its cutting-edge technology, capable of detecting and quantifying bacteria in just minutes—a major leap from traditional methods that typically require five to twenty days. This breakthrough is crucial for the food, pharmaceutical, and cosmetics industries, where speed and precision in microbial testing are critical to preventing contamination and costly product recalls.
The startup’s AI-powered technology combines advanced optical solutions with machine learning models, enabling real-time bacterial load measurement. This allows quality control teams to receive instant alerts in case of contamination risks, ensuring unmatched transparency and traceability. Since its launch, Spore.Bio has already secured contracts to deploy its solution in over 200 factories worldwide, spanning Europe, Africa, and North America.
With this fresh funding, Spore.Bio plans to accelerate the industrialization of its technology, aiming to manufacture hundreds of machines in the coming months. The company also intends to double its workforce from 25 to 50 employees in 2025 to support global expansion, particularly in the United States, where it is considering opening a new office.
